VRTX241122P420000
- 0.79
- 0.000.00%
Vertex Pharmaceuticals Newsroom
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Looking Into Vertex Pharmaceuticals's Recent Short Interest
S&P 500, Dow Hit Records Right After Open | Live Stock
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Market Climbs, Bitcoin Close to $100k | Live Stock
Vertex Pharmaceuticals (NASDAQ:VRTX) Pulls Back 6.9% This Week, but Still Delivers Shareholders Strong 34% CAGR Over 3 Years
Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock
Vertex Trust Sells $3.79 Million in Shares
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals: Promising Growth With Suzetrigine Potential and Strategic Diversification
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today
Market Falls on Retail Results, Bitcoin Swells, All Eyes on Nvidia | Live Stock